First Access

If you’ve subscribed to First Access, please click the stars below to indicate your rating for this newsletter, and please share any other feedback about your experience using the comment box below.

Investment Performance

No votes yet... cast yours!
No votes yet.
Please wait...
Your vote

Quality Of Writing/Analysis

No votes yet... cast yours!
No votes yet.
Please wait...
Your vote

Value For Price

No votes yet... cast yours!
No votes yet.
Please wait...
Your vote

Customer Service

No votes yet... cast yours!
No votes yet.
Please wait...
Your vote

Share your thoughts...

3 Comments on "First Access"

avatar

don johnson
Guest
0
don johnson

i think if a listing of co’s and dates of fda info releases were known we could all be millionaires with a few good guesses!! what a lottery this is!!

Jeff  Abbott
Guest
0
Jeff Abbott
Don’t know anything about this newsletter but i can tell you that Sangamo is the real deal in terms of a quality Biotech, quality science with a unique and impressive platform(zinc finger). It is a highly recommended and followed small cap developmental biotech with an impressive pipeline. That being said no matter how impressive the science, trial stages are always a crapshoot, especially the more advanced that are. I follow this company and it’s science fairly closely and my opinion is that they will show positive,significant results in their IIB results but i do not think it will be worth… Read more »
R. M. Kribs
Guest
0
R. M. Kribs

I have never had First Access, but have been stung by Marc Lichtenfeld when he wrote about Accuray (ARAY) for Xcelerated Profits. I was supposed to get a 119% return, but got a loss instead–& don`t know why. ARAY has a unique product in it`s Cyberknife, so should be worth more than $6-$7. Therefore, something must be wrong with management & as a Senior Analyst (?) Marc should have known that.

wpDiscuz